Skip to main content
. 2025 Aug 12;12:1639846. doi: 10.3389/fvets.2025.1639846

Table 1.

Pharmacokinetics of CBD and CBDA in dogs administrated with CBD isolate, CBDA isolate, CBDA FS, CBD/CBDA FS oil1.

Treatment Treatment effect
p-value4
Item CBD isolate CBDA isolate CBDA
FS
CBD2 CBDA3
CBD/CBDA FS
n 8 8 8 8 8
Cmax5 (ng/mL) 69.80 ± 35.44 235.51 ± 65.59 208.28 ± 66.05 64.66 ± 37.05 229.30 ± 145.51 *
Tmax6 (h) 2.75 ± 2.31 1.75 ± 2.58 0.94 ± 0.68 3.75 ± 2.71 1.81 ± 2.55 *
T1/2 el7,11 (h) 3.76 ± 1.22 6.19 ± 3.06 6.63 ± 2.69 4.5 ± 3.46 4.68 ± 1.97 ns
AUC8 (ng-h/mL) 420.61 ± 45.52 1255.70 ± 463.52 997.59 ± 366.4 354.45 ± 124.65 1240.97 ± 450.55 *
MRT9,11 (h) 5.73 ± 1.88 NA12 NA13 7.04 ± 4.77 7.35 ± 3.06 ns
Css10,11 (ng/ml) 42.83 ± 4.62 NA12 NA13 51.10 ± 14.92 108.90 ± 32.48 *
1

Values are means ± standard deviation.

2

Pharmacokinetics of CBD in the CBD/CBDA full spectrum treatment.

3

Pharmacokinetics of CBDA in the CBD/CBDA full spectrum treatment.

4

p-values for specific treatment comparisons are presented in Table 2.

5

Maximum serum concentration.

6

Time of maximum concentration.

7

Half-life of elimination.

8

Area under the serum concentration curve (0 to 12 hours).

9

Mean residence time.

10

Steady state serum concentration.

11

Three dogs are missing due to low concentrations.

12

For CBDA isolate treatment, values for MRT and Css were not available due to low concentrations.

13

For CBDA full spectrum treatment, values for MRT and Css were not available due to low concentrations.